|
2025 Conference Publication Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancerLiang, X., Ruan, Q., Kim, M., Yang, H., Bridle, K. and Crawford, D. (2025). Selective inhibition of PI3Kp110a enhances chemotherapy efficacy by suppressing hepatic stellate cell activation in liver cancer. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Berlin Germany, Oct 17-21, 2025. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.10.194 |
|
2024 Conference Publication Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathwayRuan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2024). CHEMOTHERAPEUTIC DRUGS INDUCE HEPATIC STELLATE CELL ACTIVATION IN HEPATOCELLULAR CARCINOMA VIA ROS- DEPENDENT PI3K PATHWAY. The Liver Meeting, San Diego Ca, Nov 15-19, 2024. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2024 Conference Publication Therapeutic targeting of a-specific PI3K improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancerRuan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2024). Therapeutic targeting of a-specific PI3K improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancerRuan, Qi, Cao, Lu, Yang, Haotian, Burke, Leslie, Bridle, Kim, Crawford, Darrell and Liang, Xiaowen (2023). Reactive oxygen species-mediated hepatic stellate cell activation via PI3K in liver cancer. EASL Congress 2023, Vienna, Austria, 21 - 24 June 2023. Amsterdam, Netherlands: Elsevier. |
